|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 38/22 | |
| A61K 38/39 | |||
| A61K 31/404 | |||
| A61K 31/443 | |||
| A61P 11/00 |
| (11) | Number of the document | 3139949 |
| (13) | Kind of document | T |
| (96) | European patent application number | 15789718.2 |
| Date of filing the European patent application | 2015-05-08 | |
| (97) | Date of publication of the European application | 2017-03-15 |
| (45) | Date of publication and mention of the grant of the patent | 2020-07-29 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2015/029926 |
| Date | 2015-05-08 |
| (87) | Number | WO 2015/172046 |
| Date | 2015-11-12 |
| (30) | Number | Date | Country code |
| 201461990425 P | 2014-05-08 | US |
| (72) |
ARNOLD, Susan, US
BALLANCE, David James, US
|
| (73) |
Phasebio Pharmaceuticals, Inc.,
One Great Valley Parkway Suite 30, Malvern, Pennsylvania 19355-1423,
US
|
| (54) | COMPOSITIONS COMPRISING A VIP-ELP FUSION PROTEIN FOR USE IN TREATING CYSTIC FIBROSIS |
| COMPOSITIONS COMPRISING A VIP-ELP FUSION PROTEIN FOR USE IN TREATING CYSTIC FIBROSIS |